Today's Technical View on Sanofi and Keryx: Pharma Companies Yield Strong Returns

  Today's Technical View on Sanofi and Keryx: Pharma Companies Yield Strong
                                   Returns

PR Newswire

LONDON, February 26, 2013

LONDON, February 26, 2013 /PRNewswire/ --

Drug companies work on precarious grounds. Their stock may go up and down
based on the future expectations about their drugs. Keryx Biopharmaceuticals
Inc. (NASDAQ: KERX) scored new 52-week high despite having no drug in the
market. The stock is basically moving up on the expectation of its drug
candidate receiving FDA approval. On the other hand, Sanofi (NYSE: SNY) also
reached a new high on the strength of its existing and potential drug
portfolio. StockCall initiated free in-depth technical analysis on Sanofi and
Keryx Biopharmaceuticals which are currently available upon sign up at

http://www.stockcall.com/research

Keryx Biopharmaceuticals Inc. Touches New 52-Week High

Keryx Biopharmaceuticals Inc. recently reported positive results from the
third phase of its Zerenex trials. The drug is designed for treating patients
with End Stage Renal Disease. Zerenex may be presented for the FDA approval in
2014. The company is already arranging financing for launching the drug as it
offered 55 million shares in a public offering in January. Sign up for the
free technical analysis on Sanofi at

http://www.StockCall.com/SNY022613.pdf 

Keryx's stock is up 108 percent in the past 52 weeks and with the positive
news about its drug candidate the momentum is likely to continue. The company
has been at the center of a number of lawsuits. However, the cases are
expected to have only minor negative impact on the company.

Another negative point relates to the company's dependence on its only drug
candidate. Whether the drug will receive FDA's approval or not is up for
speculation, the drug's potential to generate revenue after receiving approval
is also open to scrutiny. In case, the drug fails to get approved or fails to
perform well after approval, the company's fortunes will be in a grave danger.

Despite all the tailwinds, the company is in a solid financial position. It is
preparing well to arrange funding for the proper launch of the drug. Also the
drug itself has very high chances of getting approved. Overall, Keryx
Biopharma seems to have a promising future ahead.

Sanofi Reports Flat Revenue for Fourth Quarter

Sanofi has been hitting its new-high recently. The pharma company's
Lixisenatide also got accepted for review by FDA. The company also received
FDA approvals for its drugs last year and its stock is expected to perform
well on the back of the performance of new drugs. The company stock is up 23
percent in the past 52 weeks and it also offers 3.62 percent dividend yield.
Overall, the stock offers an attractive investment opportunity for both value
and income investors. Berkshire Hathaway holds interest in the company,
underlining the growth potential of its stock. Abrams Capital Management also
has stake in Sanofi. Download the free report on Keryx Biopharmaceuticals Inc.
by registering at

http://www.StockCall.com/KERX022613.pdf 

The company has impressive prospects for the future and it is also looking to
grow through acquisitions. Sanofi is said to be interested in acquiring
Regeneron Pharmaceuticals Inc. Both companies are already collaborating for
developing cancer therapy. For its fourth quarter, Sanofi reported flat
revenue. It also provided conservative estimates. However, the overall
scenario for the company looks bright and its stock is expected keep up the
momentum. The company is also looking to get FDA approval for Lemtrada and it
may prove to be a positive catalyst for the stock.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com 

SOURCE StockCall.com

Contact: Contact Person:William T. Knight, Email: info@stockcall.com , Contact
Number: +1-(646)-396-9857 (9:00 am EST - 01:30 pm EST)
 
Press spacebar to pause and continue. Press esc to stop.